Risk factors for positive findings in patients with high-grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette-Guérin therapy and the decision for a repeat TUR

BJU International

Volumn 105, Issue 2, 2010, Pages 202-207

  Orsola, Anna ^a   Cecchini, Lluís ^a   Raventós, Carles X ^a   Trilla, Enric ^a   Planas, Jacques ^a   Landolfi, Stefania ^a   De Torres, Inés ^a   Morote, Juan ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

BCG response; High risk; Microstaging; Noninvasive bladder cancer; Repeat TUR

Indexed keywords

BCG VACCINE;

ADULT; AGED; ARTICLE; BCG VACCINATION; BLADDER CANCER; CANCER DIAGNOSIS; CANCER GRADING; CANCER INVASION; CANCER PATIENT; CANCER RISK; CANCER SIZE; CANCER SURGERY; CANCER THERAPY; CARCINOGENESIS; CARCINOMA IN SITU; CLINICAL EVALUATION; CONTROLLED STUDY; CYSTECTOMY; CYSTOSCOPY; CYTOLOGY; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LAMINA PROPRIA; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REPEAT PROCEDURE; RISK FACTOR; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TREATMENT RESPONSE; TUMOR VOLUME;

ADMINISTRATION, INTRAVESICAL; AGED; ANTINEOPLASTIC AGENTS; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; COMBINED MODALITY THERAPY; CYSTOSCOPY; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; NEOPLASM METASTASIS; PROGNOSIS; REOPERATION; RISK FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 74049122442     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08694.x     Document Type: Article

References (30)

1. Nieder AM, Soloway MS. Eliminate the term 'superficial' bladder cancer. J Urol 2006 175 : 417 418
2. Skinner EC. The best treatment for high-grade T1 bladder cancer is cystectomy. Urol Oncol 2007 25 : 523 525
3. Jakse G, Algaba F, Malmstrom PU, Oosterlinck W. A second-look TUR in T1 transitional cell carcinoma: why? Eur Urol 2004 45 : 539 546
4. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008 54 : 303 314
5. Nieder AM, Brausi M, Lamm D et al. Management of stage T1 tumors of the bladder: International Consensus Panel. Urology 2005 66 (Suppl. 1 108 125
6. American Urological Association. Clinical Guidlines. Available at: http://www.auanet.org/guidelines. Accessed April 2009
7. Herr HW, Donat SM, Dalbagni G. Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? J Urol 2007 177 : 75 9
8. Divrik RT, Yildirim U, Zorlu F, Ozen H. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J Urol 2006 175 : 1641 1644
9. Orsola A, Cecchini L, Morote J. Re: Marko Babjuk, Willem Oosterlinck, Richard Sylvester et al. EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder. Eur Urol 2008; 54: 303-14.
10. Eur Urol 2009 55 : e15 6
11. Schips L, Augustin H, Zigeuner RE et al. Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer? Urology 2002 59 : 220 223
12. Herr HW, Badalament RA, Amato DA, Laudone VP, Fair WR, Whitmore WF Jr. Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression. J Urol 1989 141 : 22 9
13. Solsona E, Iborra I, Dumont R, Rubio-Briones J, Casanova J, Almenar S. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol 2000 164 : 685 689
14. Herr HW. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. J Urol 2005 174 : 2134 2137
15. Cottrell L, Nairn ER, Hair M. Consistency of microstaging pT1 bladder transitional cell carcinoma. J Clin Pathol 2007 60 : 735 736
16. Orsola A, Trias I, Raventos CX et al. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. Eur Urol 2005 48 : 231 238
17. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. World Health Organization Classification of Tumors. Tumors of the Urinary System and Genital Organs. Lyon : IARC Press, 2006 : 90 109
18. Herr HW. Age and outcome of superficial bladder cancer treated with bacille Calmette-Guerin therapy. Urology 2007 70 : 65 8
19. Kriegmair M, Zaak D, Rothenberger KH et al. Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. J Urol 2002 168 : 475 478
20. Brauers A, Buettner R, Jakse G. Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early? J Urol 2001 165 : 808 810
21. Sylvester RJ, van der Meijden AP, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006 49 : 466 467
22. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodriguez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 2000 163 : 73 8
23. Kiemeney LA, Witjes JA, Heijbroek RP, Koper NP, Verbeek AL, Debruyne FM. Should random urothelial biopsies be taken from patients with primary superficial bladder cancer? A decision analysis. Members of the Dutch South-East Co-Operative Urological Group. Br J Urol 1994 73 : 164 171
24. Fernandez-Gomez J, Solsona E, Unda M et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: multivariate analysis of data from four randomized CUETO trials. Eur Urol 2008 53 : 992 1001
25. Denzinger S, Fritsche HM, Otto W, Blana A, Wieland WF, Burger M. Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach? Eur Urol 2008 53 : 146 152
26. Kamat AM, Dinney CP, Gee JR et al. Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer 2007 110 : 62 7
27. Andius P, Johansson SL, Holmang S. Prognostic factors in stage T1 bladder cancer: tumor pattern (solid or papillary) and vascular invasion more important than depth of invasion. Urology 2007 70 : 758 762
28. Briggs NC, Young TB, Gilchrist KW, Vaillancourt AM, Messing EM. Age as a predictor of an aggressive clinical course for superficial bladder cancer in men. Cancer 1992 69 : 1445 1451
29. Mallows CL. Some comments on Cp. Technometrics 1973 15 : 661 675
30. Vrabie CD, Petrescu A, Waller M. Molecular changes in superficial bladder cancer. Rom J Morphol Embryol 2007 48 : 131 138